Abnormal Cardiac [I]- Meta-Iodobenzylguanidine Uptake in Multiple System Atrophy

[I]-Meta-iodobenzylguanidine (MIBG) myocardial scintigraphy is useful for distinguishing multiple system atrophy (MSA) from Parkinson disease. In this study, longitudinal observation using MIBG myocardial scintigraphy was carried out in patients with MSA to evaluate the association of myocardial MIBG uptake with clinical features. A total of 96 MIBG examinations were performed in 52 patients with MSA. The heart/mediastinum (H/M) ratio of MIBG uptake at 240 minutes after injection was below the lower limit in 16 patients with MSA (31.3%). Overall, the H/M ratio correlated with neither disease duration nor severity. In the follow-up observations, the H/M ratio did not show any specific trends, in contrast with the continuous decrease observed in patients with Parkinson’s disease. This data clearly showed that cardiac MIBG uptake cannot necessarily be preserved in patients with MSA and that approximately 30% of patients with MSA showed decreased MIBG uptake without any correlation to disease duration or severity. 2010 Movement Disorder Society

[1]  G. Cossu,et al.  Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy , 2009, Movement disorders : official journal of the Movement Disorder Society.

[2]  T. Müller,et al.  Homocysteine levels after acute levodopa intake in patients with Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[3]  O. Suchowersky,et al.  Neuropathy as a potential complication of levodopa use in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[4]  Y. Nishiyama,et al.  Low myocardial MIBG uptake in multiple system atrophy with incidental Lewy body pathology: An autopsy case report , 2008, Movement disorders : official journal of the Movement Disorder Society.

[5]  E. Aasheim,et al.  Peripheral Neuropathy and Severe Malnutrition following Duodenal Switch , 2008, Obesity surgery.

[6]  L. Lopiano,et al.  Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcome , 2007, Movement disorders : official journal of the Movement Disorder Society.

[7]  S. Harik,et al.  Neurologic complications of gastric bypass surgery for morbid obesity , 2007, Neurology.

[8]  A. Kakita,et al.  Degeneration of Cardiac Sympathetic Nerve Begins in the Early Disease Process of Parkinson’s Disease , 2007, Brain pathology.

[9]  A. Kakita,et al.  Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy , 2006, Autonomic Neuroscience.

[10]  Ph.D. Kenichi Kashihara M.D.,et al.  Myocardial 123I-MIBG scintigraphy in patients with PSP, CBD and MSA , 2006, Journal of Neurology.

[11]  Y. Katayama,et al.  Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson’s disease , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[12]  D. Nyholm,et al.  Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease , 2005, Neurology.

[13]  S. Braune.  The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes , 2001, Clinical Autonomic Research.

[14]  Mari Yoshida,et al.  alpha-Synuclein-immunoreactive structure formation is enhanced in sympathetic ganglia of patients with multiple system atrophy. , 2005, Acta neuropathologica.

[15]  Sid Gilman,et al.  Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS) , 2004, Movement disorders : official journal of the Movement Disorder Society.

[16]  P. Dyck,et al.  A controlled study of peripheral neuropathy after bariatric surgery , 2004, Neurology.

[17]  G. Abbruzzese,et al.  Does parkin play a role in the peripheral nervous system? A family report , 2004, Movement disorders : official journal of the Movement Disorder Society.

[18]  W. Kuhn,et al.  Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. , 2004, Archives of neurology.

[19]  T. Iwatsubo,et al.  Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. , 2004, Acta neuropathologica.

[20]  G. Gronseth,et al.  Challenges in the identification of cobalamin-deficiency polyneuropathy. , 2003, Archives of neurology.

[21]  R. Obeid,et al.  Vitamin B-12 status, particularly holotranscobalamin II and methylmalonic acid concentrations, and hyperhomocysteinemia in vegetarians. , 2003, The American journal of clinical nutrition.

[22]  Nicholas W Wood,et al.  Parkin disease: a phenotypic study of a large case series. , 2003, Brain : a journal of neurology.

[23]  H U Rehman,et al.  Multiple system atrophy , 2001, Postgraduate medical journal.

[24]  L. Metman,et al.  Cardiac Sympathetic Denervation in Parkinson Disease , 2000, Annals of Internal Medicine.

[25]  K. Druschky,et al.  Differentiation of Parkinson’s disease and multiple system atrophy in early disease stages by means of I-123-MIBG–SPECT , 2000, Journal of the Neurological Sciences.

[26]  I Litvan,et al.  Consensus statement on the diagnosis of multiple system atrophy , 1998, Journal of the Neurological Sciences.

[27]  M. Yoshita,et al.  Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy , 1998, Journal of the Neurological Sciences.

[28]  E. Fine,et al.  The neurophysiological profile of vitamin B12 deficiency , 1990, Muscle & nerve.

[29]  J. Weis,et al.  Differential effects of nerve, muscle, and fat tissue on regenerating nerve fibers in vivo , 1989, Muscle & nerve.

[30]  R. Hughes,et al.  Peripheral neuropathy. , 1982, The New England journal of medicine.